Background Cardiovascular disease is common in older adults with end-stage renal disease
who are undergoing regular dialysis, but little is known about the prevalence and extent of …

Background We conducted a double-blind, randomized, placebo-controlled trial to determine
the effects of oral cyclophosphamide on lung function and health-related symptoms in …

This scientific statement reviews the scientific data for cardiac computed tomography (CT)
related to imaging of coronary artery disease (CAD) and atherosclerosis. Cardiac CT is a CT …

Significant heterogeneity of clinical presentation and disease progression exists within
chronic obstructive pulmonary disease (COPD). Although FEV 1 inadequately describes this …

This Review provides an updated approach to the diagnosis of idiopathic pulmonary fibrosis
(IPF), based on a systematic search of the medical literature and the expert opinion of …

Background Endobronchial valves that allow air to escape from a pulmonary lobe but not
enter it can induce a reduction in lobar volume that may thereby improve lung function and …

Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However, …

Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic
sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung …

Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related
interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although …

Background Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma)
often has a devastating outcome. We compared myeloablative CD34+ selected autologous …